AG013

BIOLOGICAL2 trials

Sponsors

ActoGeniX N.V., Oragenics, Inc.

Conditions

Oral Mucositis

Phase 1

Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck

CompletedNCT00938080

ActoGeniX N.V.Oral Mucositis

Start: 2009-09-30End: 2012-09-30Updated: 2014-01-07

Phase 2

Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day

TerminatedNCT03234465

Oragenics, Inc.Oral Mucositis

Start: 2017-07-18End: 2020-07-13Updated: 2020-11-23